Aphria (TSX:APH; OTCQB:APHQF) announced on Thursday (February 1) it might be willing to part ways with its assets in the U.S. cannabis market, after months of being embroiled with regulators on the legality of these.

Aphria announced it is actively looking to eliminate their position in the U.S. market. According to their announcement, Aphria is considering “strategic alternatives” to their interests below the Canadian border, “including the possible divestiture of its investments to strategic, long-term and committed investors in the cannabis industry.”


The company holds a subsidiary based in Arizona, cannabis producer Copperstate. According to a report from The Globe and Mail, Aphria plans to sell its stake to Liberty Health Sciences (CSE:LHS) a cannabis operator, which launched with the support of Aphria.

“The two sides have all but agreed on a price, Mr. Neufeld says, but the transaction has not yet been finalized and requires final approval from the controlling shareholders of Copperstate,” The Globe and Mail wrote.

According to the report, Aphria is looking to also sell nearly 25 percent of their stake in Liberty Health.

“To realign things makes so much sense, to move into good hands our Liberty shares and get out of the cloud that the TSX has casted on many of us with U.S. assets,” Neufeld told The Globe and Mail.

TMX announced it would dispute Canadian cannabis companies with US interests

Last year the TMX Group, which oversees the Toronto Stock Exchange (TSX) and TSX Venture Exchange issued a notice to staff announcing it planned to stop Canadian companies from holding assets or be directly involved with operations in the U.S.

When the notice was sent Vic Neufeld, CEO of Aphria, issued a statement saying the notice was “extremely broad” and didn’t properly see the context needed for the split between federal and state laws.

Since the original notice, TMX Group and Aphria have gone back and forth on the issue. Now it appears Aphria is willing to concede to the request from the Canadian exchange.

Aphria is one of the biggest Canadian cannabis licensed producers (LPs) in the public market, and as such, it looked for ways to expand its reach. The market in the U.S. has been promised to be one of the biggest available for companies in this space.

However, on a federal level marijuana is still an illegal substance, causing Canadian exchange regulators to be particularly careful of the companies listed there.

In January the option for Canadian companies to look for options in the U.S. took another hit after Attorney General Jeff Sessions rescinded the Obama-era guidance that allowed states to states to police the legal use of marijuana.

Investor Takeaway

Experts had kept a close eye on the development of this case as it would determine the possibility of Canadian companies being able to invest and look for interests in the growing U.S. market.

Clearly, the TMX isn’t backing down and has now caused one of the biggest LPs to seek a reduction of their presence in the American cannabis market.

Aphria closed on Thursday with a 12.39 percent decrease, and while this announcement may have played a part in this reduction, the entire industry suffered a downsize from a market correction. Liberty Health finished the trading day with a 14.77 percent drop in its share price.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

  • Company surpassed 5,600 patient prescriptions for its medical cannabis products in Colombia . Prescriptions filled increased over 450% in Q3 2020 over Q2 2020
  • Khiron declared a National Strategic Project by the Government of Colombia , simplifying and accelerating administration and processes for the Company in executing strategic projects in Colombia and for export
  • Subsequent to the quarter, the Company completed a bought deal financing on November 26, 2020 , selling 32,200,000 units at a price of $0.45 per unit for aggregate gross proceeds of $14,490,000 CAD
  • Khiron signed partnerships with 15 clinics and health centres in Colombia , extending education and sales reach further across the country
  • As a result of the Company’s Doctor Zerenia TM telehealth platform more than 25% of the Company’s medical cannabis prescriptions came from outside of Bogota , expanding geographic presence of its Colombian clinics
  • Company achieved first sales of High CBD medical cannabis through private pharmacies in Peru . Additional approval received from Peru’s drug regulatory authority for Company’s High THC cannabis, with first prescriptions anticipated in Q1 2021
  • Expanded medical cannabis E-Learning platform to UK market in partnership with Medical Cannabis Clinicians Society (“MCCS”)
  • Entered an exclusive partnership with Rappi SAS, Latin America’s largest home multi-vertical app platform to distribute the Company’s CPG product portfolio, introducing Kuida products to Rappi users across the LatAm region
  • Signed agreement to distribute the Company’s Kuida TM CBD skincare brand through pharmacy, beauty retail and online markets serving the Hong Kong territory, with first orders expected in Q4 2020
  • Prudent cash use of $5 million in Q3 2020, compared with $4 million in Q2 2020, $12 million in Q1 2020 and $10 million in Q4 2019

 Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN ), (OTCQX: KHRNF), ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe announced today its financial results for the quarter ended September 30, 2020 . These filings are available for review on the Company’s SEDAR profile at www.sedar.com All financial information in this press release is reported in Canadian dollars, unless otherwise indicated.

Keep reading... Show less
  • Q3 Systemwide Pro Forma Revenue increased 18% quarter-over-quarter to $22.3 million , 170% year-over-year – Company became cash flow positive from operations in August
  • Company sale leaseback transaction with Innovative Industrial Properties scheduled to close within two weeks. As a result of close, together with proceeds from the recently closed bought deal financing, the Company will have $16 million of cash and $43 million in long-term debt
  • Company is in the process of acquiring acreage to construct up to 210,000 square feet of flowering canopy and supporting manufacturing facility in Cook County, Illinois to exponentially increase capacity in state
  • Initial guidance for 2021 with Systemwide Pro Forma Revenue of $170 -180 million and Adjusted EBITDA of $40 -50 million
  • The Company’s existing projects at maturity represent a long-term revenue and EBITDA opportunity upwards of $650 million and $250 million

4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) today announced its financial results for the third quarter of 2020. All financial information is presented in U.S. dollars unless otherwise indicated.

Third Quarter 2020 Financial Results Highlights

Keep reading... Show less
  • Q3 Systemwide Pro Forma Revenue increased 18% quarter-over-quarter to $22.3 million , 170% year-over-year – Company became cash flow positive from operations in August
  • Company sale leaseback transaction with Innovative Industrial Properties scheduled to close within two weeks. As a result of close, together with proceeds from the recently closed bought deal financing, the Company will have $16 million of cash and $43 million in long-term debt
  • Company is in the process of acquiring acreage to construct up to 210,000 square feet of flowering canopy and supporting manufacturing facility in Cook County, Illinois to exponentially increase capacity in state
  • Initial guidance for 2021 with Systemwide Pro Forma Revenue of $170 -180 million and Adjusted EBITDA of $40 -50 million
  • The Company’s existing projects at maturity represent a long-term revenue and EBITDA opportunity upwards of $650 million and $250 million

4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) today announced its financial results for the third quarter of 2020. All financial information is presented in U.S. dollars unless otherwise indicated.

Third Quarter 2020 Financial Results Highlights

Keep reading... Show less

Shareholders with losses exceeding $50,000 are encouraged to contact the firm

The Law Offices of Frank R. Cruz reminds investors of the upcoming December 1, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Aurora Cannabis, Inc. (“Aurora” or the “Company”) (NYSE: ACB ) securities between February 13, 2020 and September 4, 2020 , inclusive (the “Class Period”).

Keep reading... Show less

Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce the launch of preclinical research studies using psilocybin and N-Acetylcysteine (“NAC”) for the treatment of mild traumatic brain injuryconcussion (“mTBI”) with post-traumatic stress disorder (“PTSD”). The study is in collaboration with a multidisciplinary team of scientists and physicians at the University of Miami Miller School of Medicine under the lead of Michael E. Hoffer, M.D., professor of otolaryngology and neurological surgery.

NAC has been shown to be safe and efficacious in a phase I human clinical study in treating military personnel who had suffered mTBI. The initial research focus is to demonstrate the safety and efficacy of the combination of psilocybin and NAC using broadly accepted rodent models. Final results are expected in 2021. Once this is established, more specific work can examine dose response, medicine uptake, and medicine levels. The research team at the Miller School of Medicine has conducted prior studies involving NAC with mTBI and has a license from the United States Drug Enforcement Administration to conduct research using Schedule I controlled substances, which includes psilocybin.

Keep reading... Show less